Table 2.
Feature | K/BxN STA model | RA |
---|---|---|
Histopathological manifestations | • Leukocyte invasion • Synovitis • Pannus formation • Cartilage and bone destruction • Joint remodeling (4) |
• Leukocyte invasion • Synovitis • Pannus formation • Cartilage and bone destruction • Joint remodeling (4) |
Autoantibodies | Main driver (9) | Present – role unknown (122) |
Specificity of autoantibodies | G6PI (2) | • G6PI • Citrullinated filaggrin • Fc portion of IgG (rheumatoid factor) • Keratin • Chondrocyte gp39 • Heat-shock protein • Collagen II (123) |
Important immune cells | • Neutrophils (25) • Macrophages (41) • Mast cells? (45, 46) |
• Neutrophils • Macrophages • CD4 T cells • B cells • Dendritic cells (55) |
Pro-inflammatory cytokines | • TNF (57) • IL-1β (57) • GM-CSF (43) • G-CSF (39) • MIF (83, 84) • IL-17? (62, 63) |
• TNF (55) • IL-6 (55) • GM-CSF (44) |
Pain | Present and persists after resolution of inflammation (87) | Present and persists after resolutionof joint swelling with anti-inflammatory treatment (85) |
Common therapies | • NSAIDs (65) • TNF blockade (57) • Glucocorticoids (128, 129) • Methotrexate (130) • Tacrolimus (131) |
• NSAIDs • TNF blockade • Glucocorticoids • Methotrexate • Tacrolimus (66) |